FDA-approved PD-1 and PD-L1 antibodies, such as nivolumab, pembrolizumab, and MPDL3280A, are indicated in the treatment of melanoma, metastatic bladder cancer, and glioblastoma (99–101), although PD-1 gene editing may increase CAR T potency. Here, PDCD1 is linked to melanoma.